Back to User profile » Dr Connie Chen
Papers published by Dr Connie Chen:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L
Patient Preference and Adherence 2020, 14:119-131
Published Date: 20 January 2020
![Noteworthy comment: The paper is important because it is the first phase III trial after the registrative trial investigating the role of axitinib in Asian population.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D
OncoTargets and Therapy 2015, 8:1363-1373
Published Date: 8 June 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C
Cancer Management and Research 2014, 6:365-371
Published Date: 22 September 2014
![Noteworthy comment: Survival and best supportive care costs for patients with metastatic renal cell carcinoma (mRCC) after stopping therapy are poorly characterized yet an important aspect of patient care. This study examined survival and costs associated with BSC after 1 or 2 lines of mRCC therapy](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
Henk HJ, Chen C, Benedict A, Sullivan J, Teitelbaum A
ClinicoEconomics and Outcomes Research 2013, 5:347-354
Published Date: 9 July 2013
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C
OncoTargets and Therapy 2012, 5:287-296
Published Date: 23 October 2012